Effect of crocin of Crocus sativus L. on serum inflammatory markers (IL-6 and TNF- α ) in chronic obstructive pulmonary disease patients: a randomised, double-blind, placebo-controlled trial.
Mohammad Reza AslaniNasim AbdollahiSomaieh MatinAnahita ZakeriHassan GhobadiPublished in: The British journal of nutrition (2023)
Different factors, such as inflammation, oxidative stress, extracellular matrix degradation and apoptosis, affect the pathophysiology of chronic obstructive pulmonary disease (COPD), as a progressive disease characterised by permanent airflow limitation. Herbal supplements with anti-inflammatory and antioxidant properties can help treat certain chronic diseases. The current study aimed at investigating the preventive effects of crocin supplementation on the serum concentrations of IL-6, TNF- α , exercise capacity and pulmonary function tests (PFT) in patients with COPD. The present prospective randomised clinical trial equally divided fifty-seven patients with COPD into a placebo and an intervention group, who respectively received a placebo and crocin (15 mg twice day for 12 weeks) as a supplement. ELISA was used to measure serum levels of IL-6 and TNF- α , also PFT and exercise capacity based on 6-min walking distance test (6MWD), which was performed at the beginning and end of the study. Crocin improved the results of PFT ( P < 0·05) and 6-MWD ( P < 0·001) and exerted preventive effects by increasing the serum levels of IL-6 in patients with COPD compared with those in the placebo group ( P < 0·05). Intervention with crocin significantly lowered serum levels of TNF- α at the end of the study ( P < 0·01). The present findings suggest crocin supplementation improves exercise capacity and PFT in patients with COPD by reducing serum levels of inflammatory factors.
Keyphrases
- double blind
- oxidative stress
- clinical trial
- chronic obstructive pulmonary disease
- placebo controlled
- lung function
- rheumatoid arthritis
- randomized controlled trial
- study protocol
- extracellular matrix
- high intensity
- anti inflammatory
- phase iii
- open label
- physical activity
- end stage renal disease
- dna damage
- chronic kidney disease
- endoplasmic reticulum stress
- cystic fibrosis
- cell proliferation
- phase ii
- resistance training
- newly diagnosed
- ischemia reperfusion injury
- prognostic factors
- heat stress
- diabetic rats
- patient reported outcomes
- monoclonal antibody